Vikki Steel
Vikki Steel is the Clinical Research Associate Team Leader in the Investigator Led Clinical Trials team at Melanoma Institute Australia. Learn about her professional journey and her life outside of work here!
Vikki Steel is the Clinical Research Associate Team Leader in the Investigator Led Clinical Trials team at Melanoma Institute Australia. Learn about her professional journey and her life outside of work here!
Esther Lim is a Cancer & Immune Cell Biologist at Melanoma Institute Australia, based at Macquarie University. Read more about her latest research and personal life!
Our inspiring community has been busy hosting and participating in varied events all to support MIA - from gourmet dinners, golf days, running challenges and events held to honour loved ones.
Shafayat Chowdhury is a Clinical Biospecimen Coordinator at Melanoma Institute Australia (MIA). Read on for Shafayat's Q&A.
The four-year Government Funded Roadmap for a National Targeted Skin Cancer Screening Program commenced in March 2025. Read the 6-month update on progress so far.
Kim Dowling is a Senior Clinical Data Manager at Melanoma Institute Australia (MIA). Read on to learn about Kim's role, what she loves about her job, plus a few fun facts about her!
Researchers have reported results from an international clinical trial assessing alternative treatment options for lentigo maligna - a non-invasive condition that commonly occurs on sun-exposed areas, particularly the face.
MIA Bioinformatician Jayden Beckwith answered questions on his impactful research, what he loves about his work, and more on his life outside of work, from hidden talents to a quote he holds dear.
Our amazing community has recently been busy lacing up their runners, going alcohol-free, celebrating milestones, and honouring loved ones, all to support MIA's goal of zero deaths from melanoma! Read more about their efforts.
Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.